Shen Yu-Ting, Huang Xing, Zhang Gang, Jiang Bo, Li Cheng-Jun, Wu Zheng-Sheng
Department of Pathology, Anhui Medical University, Hefei, China.
Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Front Oncol. 2021 Jul 12;11:636365. doi: 10.3389/fonc.2021.636365. eCollection 2021.
Estrogen receptors (ESRs) and progesterone receptors (PGRs) are associated with the development and progression of various tumors. The feasibility of ESRs and PGRs as prognostic markers and therapeutic targets for multiple cancers was evaluated pan-cancer analysis.
The pan-cancer mRNA expression levels, genetic variations, and prognostic values of , , and were analyzed using the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and cBioPortal. The expression levels of ERa, ERb, and PGR proteins were detected by immunohistochemical staining using paraffin-embedded tissue specimens of ovarian serous cystadenocarcinoma (OV) and uterine endometrioid adenocarcinoma (UTEA). Correlation between immunomodulators and immune cells was determined based on the Tumor and Immune System Interaction Database (TISIDB).
, , and mRNAs were found to be differentially expressed in different cancer types, and were associated with tumor progression and clinical prognosis. ERa, ERb, and PGR proteins were further determined to be significantly differentially expressed in OV and UTEA immunohistochemical staining. The expression of ERa protein was positively correlated with a high tumor stage, whereas the expression of PGR protein was conversely associated with a high tumor stage in patients with OV. In patients with UTEA, the expression levels of both ERa and PGR proteins were conversely associated with tumor grade and stage. In addition, the expression levels of , , and mRNAs were significantly associated with the expression of immunomodulators and immune cells.
, , and are potential prognostic markers and therapeutic targets, as well as important factors for the prediction, evaluation, and individualized treatment in several cancer types.
雌激素受体（ESRs）和孕激素受体（PGRs）与多种肿瘤的发生和发展相关。通过泛癌分析评估了ESRs和PGRs作为多种癌症预后标志物和治疗靶点的可行性。
使用基因表达谱交互式分析2（GEPIA2）和cBioPortal分析了ESR1、ESR2和PGR的泛癌mRNA表达水平、基因变异和预后价值。使用卵巢浆液性囊腺癌（OV）和子宫内膜样腺癌（UTEA）的石蜡包埋组织标本，通过免疫组织化学染色检测ERα、ERβ和PGR蛋白的表达水平。基于肿瘤与免疫系统相互作用数据库（TISIDB）确定免疫调节剂与免疫细胞之间的相关性。
发现ESR1、ESR2和PGR mRNA在不同癌症类型中差异表达，并与肿瘤进展和临床预后相关。通过免疫组织化学染色进一步确定ERα、ERβ和PGR蛋白在OV和UTEA中显著差异表达。在OV患者中，ERα蛋白的表达与高肿瘤分期呈正相关，而PGR蛋白的表达则与高肿瘤分期呈负相关。在UTEA患者中，ERα和PGR蛋白的表达水平均与肿瘤分级和分期呈负相关。此外，ESR1、ESR2和PGR mRNA的表达水平与免疫调节剂和免疫细胞的表达显著相关。
ESR1、ESR2和PGR是潜在的预后标志物和治疗靶点以及几种癌症类型预测、评估和个体化治疗的重要因素。
